Not sure I'd be reading too much into that reporting. Suspect it is just a journo that is relatively new to reporting on publicly listed biotech companies including the boilerplate language on risks into their story. it's not wrong per se, just a bit unusual. But is not to my mind indicative of a higher level of risk. Stand to be corrected if this language has altered to reflect higher risk levels in this quarterly but I doubt it - not least because the CR has lowered these risks.
Ann: Third Quarter Results Presentation, page-183
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 26954 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |